ZIOP - Earnings call transcript Q4 2018 | Alaunos Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Ziopharm Fourth Quarter 2018 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, today's program may be recorded. I would now like to introduce your host for today's program, David Connolly, Vice President of Corporate Communications and Investor Relations. ahead. go Please

David Connolly

folks We're release as you. callers. few late the we and to minutes wanted call. quarter on Hi, earlier fourth our And was starting financial a afternoon today, let minutes few there give a of get last this engaged to results www.ziopharm.com. today press that Company the the that year press thank of regarding We'll issued a is a therapeutic in statements actually with on call, minute discuss our XXXX We for forward-looking the including rush these the make candidates this end during our release website, of Company and available highlights and statements representatives pipeline. a development -- potential of and are will results number

to there one Forward-looking and the including risks SEC filings. to statements our we before many And our -- and for risks beyond are begin. of XX-K is subject moving numerous housekeeping X, are item which today's control, call uncertainties in described uncertainties, slide

And of Dr. David you following the that, And for now advancing on Ziopharm call. of to and the are those not the call have. Laurence Oncology Cooper, questions I'll our of and over you open Dr. online, today's Director us After side control folks slides, turn call Mauney. and Mauney, in with the remarks, any President. may speaking are you we'll Dr. the phone their CEO Company call take to on along this For

David Mauney

today. slide and We'll thanks briefly. everybody for on we'll Thank us X it joining the and you, call on David, touch on start

and Company's achieve very a that a quarter we truly immediate transformed XXXX ability our However, success. quarter, ended strong to longer-term with

collaborations. convertible reminder, quick and raised stock, we two in million, preferred eliminated As licensing million new a and we partnerships established we $XX new $XXX agreement, a secured

demonstrated these in We position XXXX, most and are already in efforts. ever strongest execute have success in our of to

across view the our we increased have every change qualitative operational control you considerable noticed and I in operating our organization that about have that just point, tell full have We a over category. clinical can From efficiency now platforms. we

We potential to and surprise have our in and change noticeable analysts increase story. in a in investors, with to seen outreach dramatic have in recruiting interest some regards partners, a and interest we perspective, and seen considerable from posture, renewed cases,

We strongly as will as can this obviously trend forward. going we push

within recruiting focus a and in We to have made efforts our in external in continue also team adding promoting Houston. and expand and world-class active to our considerable particular with area, build progress we capacity C-suite and organization, every manufacturing

In Lead new enjoy of Directors, entirely addition, now Director. seats four the of changed occupied revamped and we six having Board naming almost an a

with bring to half, We With to seen demonstrable is it last the will shareholder have one and a Ziopharm. areas seat and search we fill over outside an seasoned be a unique who is success ongoing in to believe quarter skills valuable leader active open very a and remaining this excellent a in time our table. multiple

bringing momentum most therapy strong value bringing this in and We to continuing are tightly turn our much focused patients. investors, importantly, on more to needed

X. Now to slide

We existing expanding are each are those enjoy with world-class efforts. we and fortunate partner, to partners,

their our Controlled First, and not commitment represents partner with a we best-in-class believe entrepreneurial could our be to Regeneron for happier we IL-XX platform, efforts.

across efforts to engaged for beyond. excited more multiple and levels, throughout fruit our Our teams XXXX we bear are are and thoroughly

capital $XX there. relationship a Cancer to enjoy we in have and work pre-funded put meaningful to million Second, Center MD Anderson with over

broaden expanded the this leaders come. has administrators years While on there, we the senior CDXX, focused working for an physician group to work now relationship been to initial actively with are of and

up best-in-class and James his million China. Venture, Healthcare extend based the intellectual China commitments commitment needs and also to us. they and the Eden and clinical relationships TriArm to teams Panacea Huang cannot financial solve CAR-T BioCell programs of CDXX at in of spent our marketplace, made to $XX CAR CAR-T to delighted Therapeutics commercial for financial James Our technology be to years appreciative more looking and in and we and

tireless Lastly, Rosenberg clinic. Steve the technology NCI have and team at Dr. his of important towards in the our bringing some committed work most

that solid announce the the CRADA, We extended tumors. Development NCI Beauty today years, with for Sleeping a are the are pleased have to, two be developing committed and Agreement TCR-T Research therapies to excited and sign to treat that both Collaboration parties more to we cell

for work continue Dr. team. our with Rosenberg come We and delighted his are the years to to

of that is Importantly, releases cell issue press to work done we TCR-T make group companies be clinic ours. regulatory Rosenberg's in Dr. the by mid-XXXX. not will should be the clinic or NCI. notifications affirm today the all Historically, benefit NCI entirely Beauty to at noted to highlight It facets be to the like us in that therapy submissions allow our of does regulatory the the in Sleeping public

of conjunction the reaffirm by remind we and since XXXX, clinic with, in be will However, you supported that our with XXXX timelines. the at remain teams this track NCI, we middle and and guidance the the on Ziopharm we in we is in

IND achieved. The publicly share to assemble related NCI's been of a to you appropriate. forward being now many to which have the traded progress with trial as to able course, process all we involves understand the company, steps, As material look we

the to the express grown to is basis written. and produced meet procedures, of provide neoantigen, material T-cells T-cells govern FDA. that T-cells have Sleeping of internal operating all the and for Beauty IND the criteria. can done the assurance, release trials passed documents high and of infusing Sleeping the this of critical these numbers application be shown, the surrounding been Let example, tumors; have has some that standard targeting far. They production the TIL solid the The anticipated work of levels one system the All TCRs, than thus that has prior the scrutiny needed in granularity NCI, modified NCI that for more me the some Beauty can

very this as clinic. responsible we and before, confident for said the are abilities we we the process, to move their is NCI in As

markets we gene Sleeping viral-based means of in all impossible importantly Beauty said autologous our could enable could and to this each high non-viral nearly solution path first tumors complex pillar of for process, a back confidence and commercialize and Beauty with three TCRs, targets of of transfer example, have The this to ability of is NCI the with in the a and manufacturing Sleeping a kind has its enter this reported As be multiple also very the use programs. a types, November, assured, solid significant are Ziopharm with for with degree system process. tumors. Slide most truly clinic per a targeting We rest team Ziopharm the NCI at as that therapies enjoys see TCRs, terrific please. to poised the solid to X, patient. could to today's both be personalized for for key the target approach.

potential solid me there States statistics are American these very cases the way, of We the of year Let cancer by vast tumor latest the X,XXX,XXX and dollars a metastatic, this represents of Center, United are even solid to is. According market rates. majority in modest cancers. every opportunity how new billions Said Cancer from cancer the or significant epithelial XXX,XXX caused market tissue penetration remind deaths. deaths of that at know the now another you

penetration. therapies and each seen For for we Europe. well and XX,XXX glioblastoma Controlled a than And CDXX States more have that lymphomas with year, prospect companies approximately commercial know recurrent market and multi-billion the cases than XXX,XXX CAR-T XX,XXX even in there the valuations, new with are leukemias, more with has each cases clear modest IL-XX year, United of dollar in

occurrence In glioblastoma multiforme of the fueled $X.XX system, fact, the by by market nervous to central the or among GBM cancer the is population. in billion XXXX, global aging estimated reach increasing

a have in to past extremely the -- to for to three we so cancers, on that approval improvements solid We alone chance TCR, Slide we large our many technologies IL-XX. in survival, clear the independent is, forward financial and our can of on pillars people an with with and update drug now have you indication X, suffering now immense have upon and CAR precedent and Ziopharm from and build make status. even follow. a amazing has lives this valuations CDXX liquid does huge difference summary seen path modest current in

of of As in XX, December approximately next cash IL-XX in our we is well our us platform, G&A, Boston. as the This which quarter as NCI, the afternoon, takes primarily cash this work detailed second XXXX. we this in at into for our press primary is year. with of cash Ziopharm the source XX.X Controlled the And have release million

development In cover clinical work at cover well are MD as with pre-paid work These well done planned addition, into CDXX now them. we all Anderson resources there. exploring existing to initiatives Anderson million preclinical in XXXX, is there our of important at $XX.X other MD partnership our and

in Thank technologies changes to that, cusp we and the our are slide filled as the new confidence turn shareholder excellent a an year. I'd is with on our all to in tangible, to execute believe Company. of like are call leaf you. As we of in are now and and having and our time execute this XXXX, And clinic be we a X. turn the we to now the with ability in build Indeed, over Laurence absolutely

Laurence Cooper

well That's right, David. you. and said, Thank

in past. David that way and is a from as that a shareholders, direction. the we us which years in different well of are to and restructured company beneficial independence, we we to operational our After gained to We are XXXX, October and direction our on allows go in us autonomy detailed, license agreements

mutually these partners caliber, we investors, our relationships from and are relationships. the with support highest enhancing and expanding continued have We beneficial of

This and of enable building our developed expect programs infrastructure XX. well and as laboratory our are Slide and and capabilities to have broaden in patients number from facilities who the programs. Houston. manufacturing We expanding us will to benefit as can in-house

be tumors specific cusp milestone patient. a huge long is mid-year. is designed our This goal the are Company. that many, our Ziopharm with We a cell, is patients to with for the by will and with This of each treating be TCR-T on sought-after this therapy a it clinic neoantigen solid in to unique

cell Furthermore, therapy as come into possible. can with modified a less. In be of in made addition, rapid our the and off-hold we two our cells strides you partners the work at very CAR-T for I our manufacturing trial. viability this bring in this CDXX at to CDXX We've fast patient-derived genetically in work specific of Beauty China, year improved in to third-generation already days soon back engineering as TriArm are CAR-T second expect significant from tell Sleeping produce clinic for half clinic having the or to recently

Lastly, excitement seeing we program the our the treatment or footprint so. clinical we Controlled IL-XX glioblastoma with expand in quarter are of our over as last

patients clinicians, Sleeping this Beauty immunotherapy tumor overview, the of survival. and is interests platforms, our has our Our about into for Controlled potential of alike, that data which optimism dive there two is as showing brain IL-XX. With us captured and each let improved partners,

moving So XX. to slide

this Rosenberg, neoantigens a is being to of with trial transfer using a with platform update Dr. validation timing efforts. huge in our in get begin enthusiasm program, an therapies the me and TCR of Steven of Beauty the is non-viral in his solid collaboration specifically gene the continued and on This work tumors. for our the undertaken first-in-human Let and event our field, launch best targeting Sleeping started TCR-T the

we antigens As for NCI TCRs. genetically antigens, express Gilead We the before, to is have neoantigen Dr. process that understand modification Ziopharm. his specific identifying this to these two Rosenberg T-cells selecting the said of from the similar to TCRs targeting and team at and approaches

gene use T-cells last one been scalable to put, that number virus of Simply the targets. that in feasible. within Beauty the primary Sleeping the to the just use retrovirus. Beauty express the However, retroviruses XX. TCR treating have using is DNA using at to similar This to against patients introduced solid system retrovirus first needs Gilead commercially as our NCI dosed We has added and infuse forward per advantageous transfer year, difference the commercialization reprogram per not because are us, that is one programs expression Ziopharm we is We multiple better non-viral NCI was note and T-cells, anticipate decided Sleeping are when investment where multiple a burden a know uses needs, Slide multiple not tumors, the and and they diverge late a two from plasmids on mid-year. targeting to To TCRs neoantigens one success look neoantigens. one Sleeping single targeting itself have integrate solid on multiple tumors. patient, patient depending enrolling places but reacted having patients We at it important feel cure process. applause must to We TCR-T of on system the is TCR pathway event approach patient. non-viral meet the Beauty, same the revealed patients announcing the the community this We based with that news to to of of retrovirus.

and $XXX,XXX and patient, play per that of expressing or is international Moving using effect leukemias propagate the our to manufacture CAR-T This not low-cost are in more on CDXX for believe CAR-T the are work drug, in to problems Sleeping the markets CAR-T including the is onto seeing now less-complex Greater built the plaguing $XXX,XXX specific and costs the China out. program, best Beauty we reality infused solution is the and also is therapies space. the just T-cells. therapy CAR-T body to United rapidly ancillary on two very CDXX There cells itself the lymphomas. costs advancing to platform, States. for that We targeting unsustainable, the continents,

them to we from able system of to compared the and blood, them far fewer for remain Our DNA infuse cytokine the we the competing resting modify benefit with for patients We Beauty them be without syndrome. required half away have to can confident need specific in this therapies, of CAR-T our cell lymphodepleting signal is need expense be after processing, periods time with propagate a IL-XX one T-cells infusion. solution improve great progress. release clinic take to With risks plasmids associated we also levels. on expect made genetically enabling the may will in in day CAR, membrane-bound in to This improvements reduced from that T-cells growth Furthermore, system. into enables second believe the culture. placing working us chemotherapy. centered the viability we T-cells, the Sleeping to lengthy which this for tissue sustain go built-in proprietary we the Indeed, year for This as which to engineering cell of with efforts we've been an have CDXX

updating at clinical the forward, United this will primed States initially look MD their to to off Anderson hold. is we you recall, you are and in be this performed and when As effort team we move forward

as own build joint plans Slide this future XX. with We specific advance approach its to operating and BioCell, this also the very expect same market undertake look and have Together are the forward with and into to plans, structure in Eden the States United in shape. BioCell in the to to have teams with Eden therapy CAR-T clinic CAR-T we infrastructure relationship. rapid we'll CDXX China. thrilled have clinical met both with manufacturing Under will with the the TriArm, flexibility the China. updating The to own Greater times, venture and of personnel enterprise and our multiple take

Turning Sleeping which Beauty our second from is IL-XX. to platform Controlled

in dramatic in a witnessed programs, brisk recurrent the have patients interest with increase enrollment of with We GBM. clinical

overall months. data survival, of veledimex who Regarding sub-study, enrolling announced steroids. six XX we of we our patients patients expansion received compelling particularly than that to less on planned our XX this in the XX attribute low-dose by patients We milligrams in exceeded recently and total

veledimex of which XX reminder, of of reached to that last November the subset historical XX approximately is and more XX.X of to milligrams XX data expansion we months. completed, to overall the expect with of providing six compared with patients forward cohort we year. where quite almost this at study a We look median survival in the patients be X the As treated half will We months, than those controls showed update Society remarkable low-dose Neuro-Oncology have now steroids. for an

supported those studies recently positive demonstrating PD-X impact a on pembrolizumab by with approximately that IL-XX can Recent with associated of survival KEYTRUDA inhibition when XX.X to inhibitors checkpoint administered in with in the or the the Investigators study focus appeared immune reported tumor PD-X interferon survival is patients have PD-X the GBM, overall multi-center Medicine microenvironment. patients published that in data studies work production to benefit a shown in recurrent resection, blockade gamma tumor of who select inhibitor month, and of subset a recurrent in brain median decision immune have last combining achieved reason received system, months. of on patients. The to before is potential Our other cancers inhibition Nature PD-X a activation GBM.

our IL-XX we and demonstrated median patients patients IL-XX which of XX.X Slide and received survival, Thus, months reminder, survival a interferon production PD-X about in talked XX. about of we've before gamma. As of data, subset both optimistic a overall remain biopsy data revealed monotherapy of inhibitors. our that controlled

We trials platform began with now or combination combining our Controlled X, inhibitors inhibitors. with with a We patients recurrent third are Phase had we with enrolling nivo, in combination combining PD-X trial OPDIVO dosing OPDIVO GBM. have immune two checkpoint our with IL-XX in which of June commenced In IL-XX. cohort XXXX, dose-escalating

Regeneron's in trial X Phase quarter, Ad-RTS, IL-XX we enrollment trial open to also of expect in in the XXXX. the then, will to quarter evaluate We Libtayo in veledimex + the second or and combination second with cemiplimab complete that

year. is with Slide combination shots expect XX. rapidly. pauses in we Phase accrue without each on combination due trial checkpoint quite Regarding summary, X or this In in goal cohorts, multiple since multiple with constraints the cemiplimab, the enrollment a this this have to we the clinic to program trial

in patients tumors rapid be first-in-class advancing are that the to very Sleeping non-viral therapy CDXX-specific commercial can scaled antigens solution for we platform, manufacturing to States of we and success tumors. solid In complexity approved with China, are with treat in in standing way the a therapy cost a target the issues bringing Beauty and CAR-T, of individual TCR-T solid the our United to For poised stand in that CAR-T.

data and platform, Regeneron. Controlled begin are our expanded monotherapy IL-XX with to combination with Phase For trial a our and we have X we inhibitors, PD-X set

we at our changes for outside inside investor Company. We see and opportunities multiple and of Ziopharm, have the tangible

return for to have thank for we improve months With these much excited operator are support your done and last questions. the for you to year that, call and We the ahead. our several we during the

Operator

the of Benjamin James. Reni first Raymond Instructions] question from comes line [Operator from Our

Reni Benjamin

vein-to-vein Maybe, with it now, right of little that is see bit talk could coming after, can sort just going of as to like? exists be trial X could I what start off you just in point potentially future? Laurence, an out a sort look near the color what into regarding Phase types NCI, something all-comers, in any but the the do time, play TCR tumor care this work you of a will setting assume ever be the it product or not about that and you'll

Laurence Cooper

Sure.

Reni. you, thank Those to helpful us. questions are So, very

to but obviously metastatic highly motivated treatments. solid sort Rosenberg's So be Dr. of that first opens patients. trial sickest the will give for the some details this solid some of In the those new learnings that further enrollment, some and are expect excitement able patients, trial, referral is our of And to kind the of I just as find my these and toughest tough, is think to you typical fully the give patients tumors, on advanced These we'll we will program, of the the trial find, treat indeed to as to NCI, have we types for the ways, tumors. of Ziopharm, and pattern about the are nation's design. on clarifications

mutations the going second be solid be partnership to some opportunities but and the what to solid to in ways in words, after a there's The go tumor type. genetic types we're be nature, to I rise we're are other tumors tumor with of the by neoantigens, agnostic here won't really those gave that sense, multiple give multiple exactly going a is, the after that really to designed, We go is tumor. NCI, in into the because of going can addressed, you technology

perhaps and The So treating year, little important, when and we the stable to be into I it like made. but you think there later this tumor vein-to-vein lymphomas. really, little foot a an the There, it get cells of that you're really to what is bit win-to-win, really there's would, you'll opportunity In a details is less spectrum. solid and a be if a to liquid solid leukemias than across race between opportunity the fast-growing is get the actually longer, for those pressured made ability cells. is patient product time, the see cancers obviously, as is receive tumors, for the to medically

that's can is, care, the So and more on Ren, that is And then, as explain a it last probably I that one in would, point if TCR question, the manufacturing space. you take bit part. there, about really far a or as interesting very rapid of a little

those the for essentially these think as the program, programs, -- the moment program and you'll is alike, months essentially build than programs map more cohesive And a all my in future three I the assured, of to and at upon opportunities actually have still, you our and rest to of calibrated Ren, and investors mind, for rights its will give I carefully that to program, in three to come. programs its have Ziopharm, has of to investment, but see all story our TCR lines us enticing together, summation so, Ziopharm importantly CAR building essentially IL-XX our And the of more synergize parts. we summation that the you,

Reni Benjamin

how how about you to and expression think, process, Sleeping utilizing has thinking the mentioned to use? through I do the do remarks, the you patient utilizing prepared Beauty antigens, decide is NCI equivalent system. for, guess, the you from that How and many and antigens patient, this program of multiple gone kind antigens control established in during antigens already TCR the with multiple sticking of kind just And multiple I of

Laurence Cooper

Yeah, questions again sophisticated here.

level T-cell expression of the the threat. terms tumor the to the B relative drive, respect, of T-cells expression, A The of A of the act has this function will for versus would, the can the B antigen that's by cells, highly a analogy one, of A T-cell expand the load have the T-cells effectual pattern knock against their actually within in to will if the in dominant B specific so in level essentially the is here, here, against the T-cells very to receptor respond recycle you favor will and expressing antigen that out microenvironment dialog less more instance and the receptor that So of propagate less. antigens, antigen need, expressed number dialog your that at reduced because less of antigen and essentially

with simplicity more So essentially know the the solve themselves, mechanism are is other picking antigen, that that also of In and antigens But multiple to Dr. identification the target you that I way only The work, this picking or using of you the to it's while non-viral real is that using approach. antigen and partner viral-based those there if into to to be when to really wonder system feasible using per to not would, to than plasmids the Picking TIL make where of of effector that you're put the it's right because that, pack not course, able the work built-in step, and plasmids to your the antigens make We T-cells, just T-cells TILs products, the the more a input what business. answer the remission neoantigens and simply one. of here, for it's how modified using there, a and product It's per the that make process, The we just and separate do some is they essentially the function cost level from itself important, one then able those with patient know is one is heterogeneity the T-cell that heterogeneity words, than one's really is using in already run very than when Sleeping best product is simply question selection second system this sense if a have Beauty issue expression. gas. you plasmids. and would, Rosenberg's be patients out going using of is will more allows TIL, in up is of non-genetically because -- grown and the patient. reduction into the has TIL, patients. of scalable of a receptor products expanded they those the the work T-cells, of of the excitement, of reproducible the next those because

the the essentially into So these and system, you T-cell Beauty have fresh, can T-cells, to graft young Sleeping receptor with its scalability, do that.

Reni Benjamin

multiple maybe might talk an me, trips bit when sort manufacturing And, I just I you Can or the a to about, BioCell, as be to any begin when you mentioned we one the estimate Thanks. China. guess, Eden to know see studies for one final just color? complete, of regarding might little

Laurence Cooper

year Yeah. here. the the of come and will all that really remainder through Yeah,

training, say to basically been we of just and much today, timeframe. China going me People online, is witnessing essentially been going a such coming blink it a can have infrastructure progress venture to the within an started have Let joint to hired, progress eye. since all GMP's into be have remarkable short is that basically how place, people made that, in this

TriArm, positioned a partners keeps momentum and care, if its Eden think will going, BioCell point I that well be And to of sooner attest so, with rather later. than

Operator

Morgan. Joseph the next from line J.P. of Our Eric comes question from

Eric Joseph

sort can just what on IL-XX regimen, you more of was fully ongoing docs couple maybe in of a patients from accrued, latest -- year, I combo study preliminary studies. rationale a follow-up monotherapy duration the in from I'm can guess the expansion next bit we number use later set of the the to that the on what's steps program. on a how and Just bit when and you feedback if [indiscernible] or little see relation of particularly valuable of a the feedback got terms if data elaborate steroid-free of PD-X little low-dose and sort just with the docs stage wondering you on design, this

Laurence Cooper

Yeah. Thanks, Eric.

really the So order or we or to just know, is of taking that you low-dose the I and steroids, questions with steroid-free are something low know as our last XX.X this have XX now six recipe, test of here, activator patients the we had think terms in anxious at low-dose dose the had clinician is for think partners steroids. patients very gave that of and milligrams -- because XX in investors check, tell veledimex playbook those months a and with that the milligram we very what essentially magic and living ligand, us story veledimex, the steroids that a interesting

So that survival when physicians, really to them, Eric, collaborated that have on steroids. And the a low-dose patients because share were least steroids. the to sub-study, XX we as trial the we magic delighted, low-dose the half with month now the recipe -- anxious head share That nodding met at the and are story, physicians acceptance. we that with the anxious we're lot of is, with in of guided just said, the and we and think were I've

of low-dose and feasible now have veledimex, injection patients. completely those received is to to steroids, of into to their direct the undergo patients optimistic and this very have essentially we're neurosurgery, a milligrams to adenovirus for for So XX receive brain,

or reporting Eric, expansion already patients. that last sub-study ticking September study now accrued, the started basically quarter, the the year, of is it's of -- we of last those and you data, would, and if -- so clock In sub terms on that

update this on marching essentially patients of to bolus the investors survival of end and year overall we'll that So through year. are patients get of those towards this the the now

data are those in In sets, PD-X the terms hand. essentially of are sets data also

As think, you our we cohorts data call, heard that on treated year. two the trial last in, and accumulating with started in June nivo now of Phase-X have I

the of will forward quite So and we look this the the for third patients. for those in Street of Again, actually also data nicely the their cohort -- and updating look set data that. some is we as overall survival overall patients, survival, those to year opened maturing that cohort at terms of begin mature to dosing we just

David Mauney

add is physicians then, We to XX get this you're of the was low-dose some some look just mean a data. Yes, the hospitals, enrollment unknown. I information than gotten was more a look we've where looking just a biology and thing were to for you mean, at bit I Since started into I'll a our It it's obviously, going this mean, the when untested. ago, dramatically, a comment, look not do to we're steroids, the enrollment biopsy Ziopharm, that, that gotten inbound result, for just Eric, what when feedback up We've biology, comes veledimex. rates and interest and with by year. we our at bit I milligrams if at have rates. from you David. as on I accident qualitative gone technology, for were is think and one answer quantitative little have I a more year one

momentum if have think at should just three across telling. it the pretty all I programs, So you be look we

Eric Joseph

you a is I whether both that a a the cohort, guess, of it forward information -- interest whether understand kind the might actually data registration here wait, potentially? is for move approaches there PD-X still waiting of wait -- before the do combination kind consideration you given to study need moving with potential forward whether you how with expansion might curious I to or guess, monotherapy -- you you you in have more fact much just I'm on

Laurence Cooper

that Yeah, goal for question. I on a The we way about that's is two shots great registration. have it think mean, I

with for and the lot will IL-XX monotherapy, on around give a dataset, of monotherapy a trial. to PD-X. of that, But expanded XX holds if combine this plus survival double enthusiasm have rationale registration data we that the compelling have months this to We with down

second roughly And data in study. and out, the essentially same both look you would, will start that around see we'll so, as if that the out. time, registration the it coming of essentially data of We'll plays design to that come have opportunity second sets

Operator

comes from Lee Sean the line from C. question Our H. of next Wainwright.

Sean Lee

have OPDIVO could and with how ongoing and I program, do with in bit that quick X upcoming out? studies contrast the a with regimen, the a for on you of treatment populations, to study Libtayo, just expect play little you two one IL-XX the terms compare patient Phase those

Laurence Cooper

you, Thank Yeah. Sean.

safe time inhibitor to that important nivo cohort is PD-X reassurance with gives very IL-XX, data dosing able third X that folks because a and Phase the to been with first a now Street us have So, that combination. the this the really put by in guiding is were the

IL-XX, patient all-comers essentially put Phase similar, do terms trial direct who learning, will in look Phase allows dosing so to going trial recurrent basically would, line of PD-X of us of study. of inhibitor, we its now X mechanics the That You it's X the to sight Phase treat directly basically if accelerated so feeds figured together, the the the two dosing and population accrual drugs and to -- the because immunotherapies then patients how recurrent surgery, pattern to a put in together into built, it have powerful out in cemiplimab the have of how and with the GBM. terms the of very of essentially, that you these a these on ability to but of with is data GBM the with two to X the can be that all

Sean Lee

see I we this that information some regarding the dosing OPDIVO see. in the study different Would year? from

Laurence Cooper

fair Yeah, that's think I to say.

give terms in OPDIVO cohort of an the update the the and begin this some of in year. data year this safety give and in study initial data that survival on will to on We terms overall dosing,

Operator

We session Everyone, ladies this you, well day. as conclude gentlemen, And program. and great as Thank the for thank does have your today's participation. question-and-answer a you.

Alaunos Therapeutics (TCRT) 5 Mar 192018 Q4 Earnings call transcript